vimarsana.com

ஐரோப்பிய பாராளுமன்றம் மெப்ஸ் ஆன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Patent waiver not enough for vax rollout: WTO chief

Patent waiver not enough for vax rollout: WTO chief ​ By IANS | ​ 0 Views Nigeria s Ngozi Okonjo-Iweala proposed as new WTO chief. Image Source: IANS News Brussels, May 21 : World Trade Organization (WTO) Director-General Ngozi Okonjo-Iweala has argued in favour of expanding Covid-19 vaccine production and ending export restrictions, saying that getting a patent waiver would not be enough. She said this when answering a question on what measures are needed to accelerate equitable access to vaccines during a meeting of the European Parliament s Committee on Trade, Xinhua reported. Getting the Intellectual Property (IP) rights waiver for vaccines will not be enough, she said on Thursday.

Patent waiver not enough for vax rollout, expand production: WTO chief

World Trade Organization (WTO) Director-General Ngozi Okonjo-Iweala has argued in favour of expanding Covid-19 vaccine production and ending export restrictions, saying that getting a patent waiver would not be enough. She said this when answering a question on what measures are needed to accelerate equitable access to vaccines during a meeting of the European Parliament s Committee on Trade, Xinhua reported. Getting the Intellectual Property (IP) rights waiver for vaccines will not be enough, she said on Thursday. Okonjo-Iweala listed three other routes, namely, reducing export restrictions and reinforcing supply chains for vaccines, working with manufacturers to expand production, and transferring the necessary technology and expertise to produce the complicated vaccines.

Patent waiver not enough for COVID-19 vaccine rollout: WTO chief

Ngozi Okonjo-Iweala addresses a meeting of the World Trade Organization's General Council in Geneva, Switzerland, on March 1, 2021. (WTO/Handout via Xinhua) Okonjo-Iweala listed three other routes, namely, reducing export restrictions and reinforcing supply chains for vaccines, working with manufacturers to expand production, and transferring the necessary technology and expertise to produce the complicated vaccines. BRUSSELS, May 20 (Xinhua) .

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.